

1 • **Title**

2 Expression of insect $\alpha 6$ -like nicotinic acetylcholine receptors in *Drosophila*
3 *melanogaster* highlights a high level of conservation of the receptor:spinosyn
4 interaction

5

6 • **Author names and affiliations.**

7 Trent Perry¹ – corresponding author.

8 Jason Somers¹

9 Ying Ting Yang¹

10 Philip Batterham¹

11

12 ¹Bio21 Institute - Genetics Department, The University of Melbourne,
13 Parkville, 3010, Victoria, Australia

14

15 trentp@unimelb.edu.au

16 j.somers@pgrad.unimelb.edu.au

17 ytyang@unimelb.edu.au

18 p.batterham@unimelb.edu.au

19

20 • **Corresponding author.**

21 Trent Perry

22 Bio21 Institute – Genetics Department, The University of Melbourne, 30

23 Flemington Road Parkville, Victoria Australia 3010.

24 Phone: +61383442362

25 Fax: +61393475352

26 Email: trentp@unimelb.edu.au

27

28 **Abstract** [SEP:SEP]

29 Insecticide research has often relied on model species for elucidating
30 the resistance mechanisms present in the targeted pests. The accuracy and
31 applicability of extrapolations of these laboratory findings to field conditions
32 varies but, for target site resistance, conserved mechanisms are generally the
33 rule rather than the exception (Perry et al., 2011). The spinosyn class of
34 insecticides appear to fit this paradigm and are a pest control option with
35 many uses in both crop and animal protection. Resistance to spinosyns has
36 been identified in both laboratory-selected and field-collected pest insects.

37 Studies using the model insect, *Drosophila melanogaster*, have
38 identified the nicotinic acetylcholine receptor subunit, *Dα6* as an important
39 target of the insecticide spinosad. (Perry et al., 2007; Watson et al., 2010).
40 Field-isolated resistant strains of several agricultural pest insects provide
41 evidence that resistance cases are often associated with mutations in
42 orthologues to *Dα6* (Baxter et al., 2010; Puinean et al., 2013).

43 The expression of these receptors is difficult in heterologous systems.
44 In order to examine the biology of the *Dα6* receptor subunit further, we used
45 *Drosophila* as a model and developed an *in vivo* rescue system. This allowed
46 us to express four different isoforms of *Dα6* and show that each is able to
47 rescue the response to spinosad. Regulatory sequences upstream of the *Dα6*
48 gene able to rescue the resistance phenotype were identified. Expression of
49 other *D. melanogaster* subunits revealed that the rescue phenotype appears
50 to be *Dα6* specific. We also demonstrate that expression of pest insect
51 orthologues of *Dα6* from a variety of species are capable of rescuing the

52 spinosad response phenotype, verifying the relevance of this receptor to
53 resistance monitoring in the field. In the absence of a robust heterologous
54 expression system, this study presents an *in vivo* model that will be useful in
55 analysing many other aspects of these receptors and their biology.

56

57

58 **Keywords** 

59 Spinosyn

60 Spinosad

61 Nicotinic acetylcholine receptor

62 Insecticide resistance

63 *Drosophila melanogaster*

64 Pest insect

65 ¹Abbreviations

66

¹nAChR – nicotinic acetylcholine receptor

67 **1. Introduction** [SEP]

68 **1.1 The targets of insecticides are often conserved, as are target-site**
69 **mediated resistance mechanisms.**

70 Many insecticides target receptors that mediate neurotransmission.
71 Disruption of this crucial and sensitive system leads to the rapid death of pest
72 insects with low chemical concentrations - highly desirable commercial
73 properties for an insecticide. However, the nervous system of insects has
74 proven to have an inbuilt plasticity, whereby evolution can select for
75 resistance via the modification, or even loss, of a neural receptor, overcoming
76 this severe selection pressure (Perry et al., 2011). This should not be
77 surprising as many insecticides emulate naturally produced plant defence
78 compounds (e.g. pyrethrin and nicotine) to which insects have likely been
79 exposed throughout their evolutionary histories.

80 In some cases the precise target and mode of action of insecticides
81 has been discovered using the model insect, *Drosophila melanogaster* (Perry
82 et al., 2011). That targets identified in *D. melanogaster* have typically been
83 shown to be the targets in pests (Perry et al., 2011), underscores the
84 evolutionary conservation of receptors involved in insect neurotransmission.
85 Therefore the extensive genetic/genomic resources and technologies
86 available in *D. melanogaster* can be used to identify pest insect targets, even
87 before resistance evolves in the field (McKenzie and Batterham, 1998).

88 Beyond being useful for pest control, neurotoxic insecticides are
89 agonists, antagonists, non-competitive blockers or allosteric modulators that
90 can be powerful reagents in examining the biology of different receptor
91 classes, particularly when used in *D. melanogaster*. An example of this is

92 provided by the GABA-gated chloride channel subunit encoded by *Rdl*,
93 targeted by dieldrin (Ffrench-Constant, 1994) which depending on its co-
94 assembled subunits has varying sensitivities to picrotoxin and bicuculline
95 (Zhang et al., 1995) and was probed for its role in sleep using the drug,
96 carbamazepine, also using the resistant allele, *Rdl*^{A302S} (Agosto et al., 2008).

97

98 **1.2 The Spinosyn class of insecticides target nAChR subtypes that** 99 **contain $\alpha 6$ -like subunits and mutations in these can confer resistance**

100 Spinosad is a mixture (85:15) of two compounds, spinosyns A and D
101 respectively, first identified as a fermentation product from a soil
102 actinomycete, *Saccharopolyspora spinosa* (Kirst, 2010). The characterization
103 of D $\alpha 6$ as a spinosad target in *D. melanogaster* (Perry et al., 2007; Watson et
104 al., 2010), has been followed by reports that in Diamondback Moth, (*Plutella*
105 *xylostella*), mutations causing truncations of the *D $\alpha 6$* orthologue, *Px $\alpha 6$* are
106 associated with recessive spinosad resistance up to 18,600-fold (Baxter et al.,
107 2010). This phenomenon has also been reported in *Bactrocera dorsalis*
108 (Oriental fruit fly) conferring 901-fold resistance (Hsu et al., 2012). Recently a
109 single point mutation (G275E) in the *Frankliniella occidentalis* (Western flower
110 thrip) orthologue, *Fo $\alpha 6$* , was reported to be associated with >350,000-fold
111 spinosad resistance in a laboratory-selected strain and detected in a field
112 collected population (Puinean et al., 2013). It has also been associated with
113 field resistance to spinosad in the melon thrip, *Thrips palmi* (Bao et al., 2014).

114 While there are examples of spinosad resistance that may be
115 explained by other mechanisms (Gao et al., 2007; Herron et al., 2014; Hojland
116 et al., 2014; Hou et al., 2014), the commonality of this mechanism where a

117 significant loss of function of a neural receptor subunit leads to survival of the
118 insect, even at high insecticide concentrations, highlights the need to better
119 understand the biology of insect nAChRs, particularly the D α 6 subunit and its
120 orthologues. The insect α 6 gene is highly conserved. Alternative splicing and
121 RNA editing of transcripts of this gene are likely to produce α 6 subunits
122 varying in pharmacological and/or electrophysiological responses when
123 assembled into pentameric receptor complexes (Grauso et al., 2002).

124

125 **1.3 Current technical limitations on studying the α 6-like receptors**

126 A number of technical difficulties currently prevent robust expression of
127 many insect nAChRs *in vitro*, hampering functional studies. Heterologous
128 expression requires co-expression of a vertebrate structural β subunit for
129 many nAChR subunits, but this method was unsuccessful for D α 6 subunits
130 (Lansdell and Millar, 2004). D α 5, D α 6 and D α 7 have highest similarity to the
131 vertebrate α 7 receptor which is capable of forming functional homo- and
132 hetero-pentameric receptor complexes. In oocyte expression studies D α 6 co-
133 expression with D α 5 and the accessory protein RIC3 yielded an
134 electrophysiological response to Acetylcholine (ACh) and spinosynA (Watson
135 et al., 2010), while a more recent study showed that D α 6 can assemble into
136 ACh responsive receptors with D α 5 or D α 5 and D α 7, as long as the RIC3
137 protein is co-expressed (Lansdell et al., 2012). The spinosyn sensitivity of the
138 D α 5/D α 6/D α 7 heteromeric nAChR has thus far not been reported. To
139 overcome difficulties studying the receptor *in vitro*, we have developed an *in*

140 *vivo* rescue system to characterize several aspects of insect $\alpha 6$ subunit
141 biology and the response to spinosyns.

142

143 **1.4 Creation of an *in vivo* system for characterising $\alpha 6$ receptor biology**

144 We have used chemical mutagenesis to generate two *D. melanogaster*
145 mutants that are highly resistant to spinosad and then successfully rescued
146 the resistance phenotype through the expression of $D\alpha 6$ isoforms, creating a
147 powerful tool for analysing $D\alpha 6$ biology. Applying the system towards studying
148 regulation of these receptors we have identified a region upstream of *D $\alpha 6$* that
149 is capable of rescuing the susceptible phenotype when used to drive the
150 expression of a wildtype subunit. Using this system to analyse pest insects,
151 we have expressed *D $\alpha 6$* orthologues from three species and show that each
152 has some capacity to restore a response to spinosad.

153

154 **2. Material and methods**

155 **2.1 Fly strains**

156 **Table 1. *Drosophila melanogaster* lines used in this study**

Name	Origin	Genotype	Stock #
Armenia ¹⁴	DGRC ¹	Isofemale line from Armenia ⁶⁰	103394
elavc155	BDSC ²	P{w ^{+mW.hs=GawB} }elav[C155]	458
Df556	BDSC ²	w*; Df(2L)s1402, P{w ^{+mC=lacW} }s1402/CyO	556
ΦX-86Fb	Basler Lab	y w M{eGFP.vas-int.Dm}ZH- 2A;+;M{RFP.attP}ZH-86Fb;+	(Bischof et al., 2007)
Dbal	Batterham lab stock	w;lf/CyO;MKRS/TM6b,Tb	
w ¹¹¹⁸	BDSC ²	w ¹¹¹⁸	5905
4775	BDSC ²	w ¹¹¹⁸ ; P{w[+mC]=UAS- GFP.nls}14	4775

157 ¹Drosophila Genetic Resource Centre

158 ²Bloomington Drosophila Stock Centre

159

160 **Table 2. *Drosophila melanogaster* lines generated in this study**

Name	Genotype	Method	Use
<i>dα6</i> ^{W337*}	<u><i>dα6</i>^{W337*}</u>	EMS mutagenesis	Spinosad resistant
<i>dα6</i> ^{nX}	No <i>dα6</i> expression	EMS mutagenesis	Spinosad resistant

FKBP59>GAL4	w ¹¹¹⁸ ;+;pPTGAL4-	P-element	Enhancer
	{ FKBP59_0.6kb}	transgenic	analysis
D α 6>GAL4	w ¹¹¹⁸ , pC3G4-	P-element	Enhancer
	{ D α 6_1.1kb};+;+	transgenic	analysis

161

162 2.2 Media preparation

163 Standard fly media (Perry et al., 2012) was used for both rearing and
 164 bioassays of the flies. Larvae for bioassays were collected using laying plate
 165 media (Perry et al., 2012).

166

167 2.3 Bioassays

168 Resistance was assayed using general media dosed with appropriate
 169 concentrations of Success™ (Dow Agrosciences, 1g/L spinosad) prior to
 170 setting as per previous studies (Perry et al., 2012). Vials, each containing 50
 171 1st instar larvae, were kept in the dark at 25°C until adult eclosion was
 172 recorded at 16-18 days.

173

174 2.4 Creation of D α 6 alleles resistant to spinosad

175 The *D α 6* recessive alleles used in this study (*d α 6*^{W337*}, *d α 6*^{nx}; Table 2)
 176 were generated using ethyl methanesulfonate (EMS) mutagenesis (Smyth et
 177 al., 1992). Approximately 250,000 embryos produced by 3000 mutagenised
 178 Armenia¹⁴ males crossed to 5000 Df556 (spinosad resistant (Perry et al.,
 179 2007)) virgin females screened with a dose of 5ppm spinosad (Success™).
 180 These were balanced using Dbal, made homozygous and the *d α 6*^{W337*}
 181 transcript was cloned using RT-PCR on isolated RNA and then sequenced.

182 The *Dα6* exons were also amplified from genomic DNA and sequenced for
 183 any changes in the *dα6^{W337*}* and *dα6^{nx}* alleles. The sequence reads of the
 184 transcript with the W337* change in *dα6^{W337*}* are shown (Supplementary
 185 figure 1).

186

187 2.5 Generating transgenic UAS expression constructs

188

189 **Table 3. Alternate splicing and A-to-I RNA editing status of UAS-α6**
 190 **constructs used in this study.**

Construct	Alternate exons	A-to-I RNA edited sites ¹
UAS-Dα6-3a8a ²	3a, 8a	4, 5 & 6
UAS-Dα6-3b8b	3b, 8b	4, 5 & 6
UAS-Dα6-3b8a	3b, 8a	4, 5, 6 & 7
UAS-Dα6-3a8b ²	3a, 8b	4, 5 & 6
UAS-Mdα6-3b8a	3b, 8a	4, 5, 6 & 7
UAS-Bovα6-3a8b ³	3a, 8b	4 & 6 Site 7 - K
UAS-Bovα6-3a8a ⁴	3a, 8a	Site 7 - K
UAS-Pxα6-3a8b	3a, 8b	5 & 6 Site 7 - K

191 ¹RNA editing sites numbered according to (Grauso et al., 2002). ² Constructs
 192 created artificially using an EcoRV cut site. ³ KP231338 and ⁴ KP231337. -
 193 Genbank Accession numbers.

194

195 **2.5.1 Cloning of *Drosophila* $D\alpha 6$ isoforms, $D\alpha 1$, $D\alpha 5$ and $D\alpha 7$.**

196 cDNA made using RNA isolated from homozygous Armenia¹⁴ flies was
197 PCR amplified (with respective subunit gene primers - Table 4). The products
198 were cloned using standard methods into the pGEM-T-easy vector (Promega)
199 and sequenced (Macrogen - Korea). Selected $D\alpha 6$, $D\alpha 1$, $D\alpha 5$ and $D\alpha 7$
200 clones were digested with NotI or EcoRI and ligated into respectively digested
201 pUASattB (Bischof et al., 2007). $D\alpha 6$ -3a8a and $D\alpha 6$ -3a8b isoforms were
202 artificially reconstructed from cDNA clones using a NotI/EcoRV double digest.
203 Bands of the correct size were gel purified and the appropriate ones ligated
204 into the pUASattB vector. Correctly oriented clones were then sequenced
205 (Table 3).

206

207 **2.5.2 Microinjection of $\alpha 6$ UAS constructs**

208 Transgenic *Drosophila* were produced using a standard procedure for
209 embryonic injections into ΦX -86Fb. Plasmid DNA (Qiagen Midiprep Kit, 100-
210 250ng/ul) was injected into the posterior pole of dechorionated 0-30 minute
211 old embryos under paraffin oil using a Femtojet with a Femtoll needle
212 (Eppendorf). For ORFs of the non-drosophilid insect $\alpha 6$ orthologues, ΦX ;
213 $d\alpha 6^{W337*}$;86Fb and ΦX ; $d\alpha 6^{nX}$;86Fb lines were generated and homozygous
214 lines were established from correctly mapped insertions.

215

216 **2.6 Microinjection into the w^{1118} line**

217 **2.6.1 Analysis of the $D\alpha 6$ enhancer region**

218 To create the *Dα6* enhancer element strains, Δ 2-3 transposase
 219 plasmid DNA (100ng/ul) was co-injected with a plasmid midiprep (Qiagen) of
 220 the construct (300ng/ul) into *w¹¹¹⁸*. pPTGAL (DGRC 1225) was used for
 221 FKBP59>GAL4 and pC3Gal4 (DGRC 1224) was used for Dα6>GAL4. These
 222 insertions were mapped to chromosomes using Dbal, made homozygous and
 223 then crossed into the *dα6^{nx}* and *dα6^{W337*}* backgrounds.

224

225 **2.7 Table 4. Primers used in this study.**

Primer	Sequence 5'->3'	Use
Da6_enhL	CGCTAATTTTCCCACTCTGC	Dα6 enhancer
Da6_enhR	CGCATATGTTTCAAATGACG	Dα6 enhancer
Da6_12F	AAYTYATHATGTTYATGGT	Degenerate PCR
Da6_14R	CATNGCNGCRAAYTTCCAYTC	Degenerate PCR
Da6_cloneR	GCTTCCGACGTATCCGTAGC	Expression construct
Da6_cloneF	GTAGCCATTCAACCCGAGAG	Expression construct
Bova6_clone F	CGGACAATTCTGGAGGGA	Expression construct
Bova6_clone R	CAGAGAGCACCTCCATGAC	Expression construct
Ma6F	CGCACCAACCAACCAACTCAGC	Expression construct
Ma6R	AGGTTTCTTGATTGTTGTTGTCTCA	Expression construct
Bova6RACE_ F	TGTGTTTCTGCTATGGCTGCCTTG	RACE

Bova6RACE_	CACTTCTGCTTCTTCGTCGGCTTT	RACE
R		
Da6_RT_L1	CAATATCTGGCTCCCAAACC	Real Time PCR
Da6_RT_R1	TCGTGAAGAGCGTGAAAACAA	Real Time PCR
CG13220_RT		
F	TGGGCAGTGCCTTCTACATTT	Real Time PCR
CG13220_RT		
R	CGTACGCACCTCGCTTGTT	Real Time PCR
Da1cloneF	GTTGGACCTGGCCTAAGATG	Expression construct
Da1cloneR1	CGCAATGTTCACTTCACTTCG	Expression construct
Da7cloneF	GATATAGAATATTCGAACTC	Expression construct
Da7cloneR	CAGCATCGCTCCTTCGCTTACG	Expression construct
Da5cloneF	GTAGAGAGCAGACAACATATCC	Expression construct
Da5cloneR	CCATATGGCTACGAGACAATA	Expression construct

226

227 **2.8 Pest insect expression constructs**

228 **2.8.1 Cloning of *Bovα6***

229 Subunits from *Bovicola ovis* were cloned using a combination of
230 degenerate primers and 5' and 3' RACE. Samples of *B. ovis* were collected
231 from sheep based at Yeerongpilly, QLD Australia (Queensland DPI) in 2006.
232 These samples were stored in RNAlater™ (Life Technologies) and processed
233 using TRIzol™ (Life Technologies) as per the manufacturers protocol. The
234 Da6_12F/Da6_14R degenerate primers were used to amplify some of the
235 *Boα6* coding region using PCR and an amplified product was sequenced
236 (Australian Genome Research Facility - AGRF). This allowed the design of

237 the *B. ovnis* specific Bova6RACE_F and Bova6RACE_R primers (section 2.7).
238 The 3' and 5' RACE (SMART™ RACE cDNA Amplification Kit, Clontech)
239 reaction products were sequenced (AGRF) to identify start and terminal
240 sequences and primers designed to clone the full length open reading frame
241 (Bova6_cloneF/ Bova6_cloneR). This ORF was then sub-cloned into
242 pUASattB (Table 3), sequenced again and transgenic lines established as per
243 section 2.5.2.

244 **2.8.2 *Mdα6* construct**

245 The *Mdα6* gene sequence had been previously published (Gao et al.,
246 2007) and the primer sequences from that study (Ma6F/Ma6R) were used to
247 clone the coding region out of cDNA made from RNA from a *Musca*
248 *domestica* spinosad susceptible strain, WHO/I (Novartis Animal Health, Basel,
249 Switzerland). This was cloned into pUASattB (Table 3), sequenced and
250 transgenic lines were established as per section 2.5.2.

251

252 **2.8.3 *Pxα6* construct**

253 A clone of the *Plutella xylostella* α6-like subunit ORF (S.W. Baxter) and
254 this was sub-cloned into pUASattB (Table 3). Transgenic *D. melanogaster*
255 lines were established as per section 2.5.2.

256

257 **2.9 Driving the UAS constructs in the resistant backgrounds**

258 **2.9.1 Creation of elav>GAL4**

259 The X-linked elavc155 driver was crossed separately into the
260 background of *dα6^{W337*}* or *dα6^{nx}* (chromosome 2) to create what will be
261 referred to as elav>GAL4 driver lines, homozygous for the driver and the

262 respective resistant allele. These lines were tested for resistance by screening
263 on media containing spinosad and also for a maintained neural expression
264 pattern, visualized by crossing to line 4775 (UAS:nGFP). These lines were
265 then used as females in any crosses to UAS- $\alpha 6$ expression constructs.

266

267 **2.9.2 The enhancer region of *D $\alpha 6$***

268 For analysis of the *D $\alpha 6$* upstream region, primers were designed to
269 amplify a 1.692kb distal intergenic region (2L:9886130..9887821, Flybase
270 release 6.02) from just inside the *D $\alpha 6$* transcript start to 184bp prior to the
271 FKBP59 transcription start site. This 1.692kb region was sub-divided into
272 623bp and 1069bp fragments using an EcoRI restriction site (2L:9887199),
273 (Figure 1A). These two smaller fragments were cloned into either PC3G4 or
274 PPTGAL4 and transgenic lines *D $\alpha 6$* >GAL4 and FKBP59>GAL4 created
275 (section 2.6.1).

276

277 **2.10 Real Time Quantitative RT-PCR**

278 80-100 first-instar larvae were collected and snap frozen for each
279 sample. Total RNA was isolated using TRIzol™ reagent (Life Technologies).
280 Each RNA sample was treated with RNase-free DNase I (Promega). 1 ug of
281 RNA sample was used in each reverse transcription reaction using
282 Superscript™ III Reverse Transcriptase (Life Technologies) and oligo(dT)₂₀.
283 To use the $2^{-\Delta\Delta CT}$ method, each set of primers was validated against the
284 control gene primer (Livak and Schmittgen, 2001). Real Time quantitative
285 PCR was carried out using a QuantiFast™ SYBR green PCR kit (Qiagen) and
286 performed on the RotorGene™-3000 (Corbett). PCR conditions were 95°C for

287 15 mins, followed by 50 cycles of 95°C for 30 sec, 61°C for 30 sec and 72°C
 288 for 30sec. Analysis was done using the $2^{-\Delta\Delta CT}$ method (Livak and Schmittgen,
 289 2001). MIQE Table is presented as Supplementary Table 1.

290

291 **3. Results and Discussion.**

292 **3.1 Generation of spinosad resistant alleles**

293 Two highly resistant *Dα6* mutants were isolated from an EMS
 294 mutagenesis and selection experiment, *dα6^{W337*}* and *dα6^{nx}* (Section 2.4).
 295 These alleles confer recessive resistance to spinosad (Somers et al., 2015)
 296 and are allelic as determined by complementation testing (not shown).
 297 Mutants homozygous for *dα6^{W337*}* are 61-fold resistant compared to the
 298 parental Armenia¹⁴ while *dα6^{nx}* are over 1000-fold more resistant (Table 5).
 299 PCR and sequencing of cDNA isolated from *dα6^{W337*}* adult RNA revealed a
 300 nucleotide G->A transition in exon 9 that changes the W³³⁷ codon to a
 301 termination codon. Sequencing of genomic DNA from the coding exons of
 302 *Dα6* confirmed this nucleotide change in exon 9, an exon common to all
 303 alternative splice isoforms.

304

305 **Table 5.** Resistance values of spinosad resistant alleles in this study

	<i>Armenia¹⁴</i> ⁽¹⁾	<i>dα6^{W337*}</i>	<i>dα6^{nx}</i>
LC₅₀	0.034ppm	2.09ppm	>40ppm
(95%CI)	(0.029-0.039)	(1.74-2.51)	
Resistance ratio	1	61-fold	>1176-fold

306 ¹ Somers et al., 2015.

307

308 No transcript was detected for $d\alpha 6^{nx}$ using PCR (Da6cloneF /
309 Da6cloneR) on cDNA generated from RNA isolated from this line (not shown).
310 This lack of $D\alpha 6$ expression was supported by Real Time PCR (primers
311 Da6_RT_L1/Da6_RT_R1) which did not detect expression of $D\alpha 6$ transcripts
312 in the $d\alpha 6^{nx}$ background control cross $elav>GAL4x\Phi X-86Fb$ (Supplementary
313 Figure 2). Sequencing of all exons from genomic DNA did not reveal any non-
314 synonymous changes in the coding region of $d\alpha 6^{nx}$. While the causal
315 molecular lesion is unknown for $d\alpha 6^{nx}$, the evidence suggests it is an allele of
316 $D\alpha 6$ that lacks expression of wildtype $D\alpha 6$ transcripts.

317 The resistance level observed for the $d\alpha 6^{nx}$ allele is higher than
318 $d\alpha 6^{W337*}$ suggesting that there could be some retained level of function of the
319 $D\alpha 6$ proteins produced by the truncation allele. This could be due to partially
320 functional truncated subunits assembling into receptors and binding spinosad,
321 or some translational read-through beyond the stop codon. For other nAChR
322 family members there is evidence that a subunit truncated at the 4th TM
323 domain is capable of being trafficked to the surface (Schulz et al., 2000).

324 The stop codon introduced by the G->A transition is 13 residues after
325 the end of the predicted third transmembrane domain (TM3). Thus a
326 theoretical protein would include TM3 which is implicated in spinosyn binding
327 (Puinean et al., 2013). This mutation is at a similar position to the one found in
328 a *P. xylostella* resistant strain (Baxter et al., 2010). In *Px\alpha 6* a splice junction
329 read-through leads to a frame-shift causing nonsense amino acids and a
330 premature stop codon. It is interesting to note the resistance difference
331 between *D. melanogaster* (61-fold) and *P. xylostella* where resistance was

332 initially 1080 fold with further selection on *P. xylostella* increasing this to
333 18,600-fold resistance. The significance of this is not clear, because while
334 comparisons between resistant and susceptible *D. melanogaster* were
335 undertaken in controlled genetic backgrounds, in *P. xylostella* they were not.
336 However taken together with the over 1180-fold resistance found for a *D.*
337 *melanogaster* strain with a deletion/inversion at the *Dα6* locus (Perry et al.,
338 2007), the 370-fold adult resistance of an EMS generated *D. melanogaster*
339 line, DAS1, an exon1/intron1 altered splice site allele (Watson et al., 2010)
340 and the >1000-fold resistance in the *dα6^{nx}* allele, there is likely to be some
341 retained function in the *dα6^{W337*}* truncated receptor that allows spinosad to
342 bind and elicit a response, albeit a reduced one.

343

344 **3.2 GAL4>UAS expression of individual isoforms is capable of rescuing** 345 **the spinosad response phenotype of the *dα6^{nx}* and *dα6^{W337*}* alleles.**

346 Four full length *Dα6* cDNAs including alternative exon 3 and exon 8
347 combinations were cloned into pUASattB (Table 3) and then inserted into the
348 3rd chromosome at the AttP landing site located at cytological position 86Fb
349 (section 2.5.1 and 2.5.2). The 2nd chromosomes were replaced with one that
350 had either the *dα6^{W337*}* allele or the *dα6^{nx}* allele, placing the rescue constructs
351 in the resistant backgrounds. The elav>GAL4 driver was created by crossing
352 the driver element on the X chromosome into the resistant allele background
353 (on the 2nd chromosome) and this was used to drive expression (section
354 2.9.1). Each cloned isoform was crossed to the driver and bioassays
355 performed to measure the response to spinosad, in both the *dα6^{W337*}* and

356 $d\alpha6^{nx}$ backgrounds. The data obtained measuring survival to eclosion on
357 various doses of spinosad (section 2.3) are presented in Figure 2.

358 At all spinosad doses tested for mortality (0.05ppm, 0.1ppm and
359 0.3ppm) we found that in both the $d\alpha6^{nx}$ and $d\alpha6^{W337*}$ backgrounds there was
360 a very significant level of corrected mortality (Abbott's correction (Rosenheim
361 and Hoy, 1989)) relative to the undosed media for our crosses driving
362 expression of any of the 4 isoforms of $D\alpha6$ (Figure 2. B and D). As expected
363 the $elav>GAL4$ x $\Phi X-86Fb$, expressing GAL4 (the empty AttP site), did not
364 exhibit significant mortality at any of the doses of spinosad for either
365 background (Figure 2. A and C). The insertion site, 86Fb has been reported to
366 have a level of leaky expression (Bischof et al., 2013) which we observed in
367 our insertion parentals. At a higher dose of spinosad tested (0.3ppm),
368 mortality is significantly different to that of their controls as opposed to other
369 background lines (Supplementary Tables 2 and 3). Interestingly there is a
370 significant difference in mortality for the different isoforms expressed in the
371 same genetic background. This suggests that some isoforms are more
372 responsive to spinosad or better able to form functional receptors than others.
373 This could possibly be due to sequence differences between isoforms
374 impacting the binding site or receptor responsiveness.

375 $d\alpha6^{nx}$ and $d\alpha6^{W337*}$ rescue experiments show that each of the
376 individual isoforms is capable of rescuing the response to spinosad. There is
377 no observed difference in the mortality of the background strains or insertion
378 parentals to undosed media or 0.05ppm spinosad for either resistant
379 background (Figure 2). This shows that both alleles are suitable for analyzing
380 rescue. While in both resistant backgrounds the parental isoform strains show

381 a level of mortality, quite clearly at the 0.3ppm dose (Supplementary Tables 2
382 and 3) this is easily distinguishable from the observed mortality for the
383 *elav>GAL4* driven isoforms.

384

385 **3.3 Analysis of the *Dα6* enhancer region**

386 **3.3.1 The region upstream of *Dα6* contains enhancer elements**

387 A 1.692kb intergenic region between the *FKBP59* and *Dα6* genes was
388 cloned and it was also sub-cloned into 1.1kb and 0.6kb fragments to analyse
389 the expression driven by this region (Figure 1A and Section 2.9.2). Initially the
390 vector pStinger was used to examine the expression pattern, this placed
391 nGFP under the direct regulatory control of each fragment. Third instar larval
392 brains from at least two independent insertion lines for each region were
393 examined for nGFP expression which was present (Supplementary Figure 3).
394 The same elements were then cloned into GAL4 expression vectors (Section
395 2.9.2). These constructs were crossed to line 4775 to drive nGFP, allowing
396 visualisation of the expression. The expression patterns observed of the
397 pStinger and the PC3G4/pPTGAL4 constructs in 3rd instar larval brains were
398 extremely similar (Supplementary Figure 3). We examined the expression of
399 the two enhancers using a pStinger *FKBP59_0.6kb* line (GFP) and a
400 UAS:RFP insertion driven by the *Dα6>GAL4* line. This cross showed the
401 expression patterns of GFP and RFP to be non-overlapping (Figure 1C).

402

403 **3.3.2 Expression pattern of *Dα6>GAL4*.**

404 The *Dα6>GAL4* driver appears to express nGFP in the cortex of the
405 central brain, most likely in nuclei of cell bodies with projections into the

406 mushroom bodies (Figure 1B and C.). There is additional nGFP possibly in
407 the cortex of the ventral ganglion. The 1.1kb fragment is adjacent to the *Dα6*
408 gene and it is likely that the nGFP marks at least a subset of cells that would
409 express *Dα6*.

410

411 **3.3.3 FKBP59>GAL4 expression pattern.**

412 FKBP59>GAL4 drives expression of nGFP in a non-overlapping
413 pattern to that of *Dα6*>GAL4 with a noticeable difference in expression in the
414 central brain (Figure 1C). It appears to be either in glial cells or in the central
415 brain cortex but in different cell bodies to those expressing nRFP driven by
416 *Dα6*>GAL4. There is also nGFP visualised in the ventral ganglion,
417 concentrated in the outer cell layer that would again suggest a glial cell
418 expression. It is also expressed at several other locations in larvae including
419 the salivary glands, a common expression artefact observed with the
420 pPTGAL4 vector rather than the enhancer itself (Sharma et al., 2002).

421

422 **3.3.4 The response to spinosad is dependent on the expression pattern** 423 **of *Dα6*.**

424 Driver lines were used to express the UAS-*Dα6*-3b8b isoform in the
425 *dα6^{nX}* background and assayed for their mortality on doses of spinosad. The
426 *Dα6*>GAL4 driver line was able to rescue the resistance phenotype (Figure
427 1D), however the FKBP59>GAL4 did not. This was found for a second,
428 independent FKBP59>GAL4 insertion line (not shown). The *Dα6*>GAL4
429 driving expression of UAS-*Dα6*-3b8b in the *dα6^{W337*}* background, confirmed a
430 capacity to rescue the spinosad response (Supplementary Table 4).

431 The corrected mortality shows a lower response to spinosad when
432 compared to the rescue observed for the *elav>GAL4* driver. At the lowest
433 dose of 0.05ppm spinosad, in the *dα6^{nx}* background, the *elav>GAL4*
434 corrected mortality (86 +/- 4) when compared to that of the *Dα6>GAL4* (41 +/-
435 9) indicates there is likely to be a higher level of expression when using
436 *elav>GAL4* and/or a greater number of cells expressing *Dα6* than when using
437 *Dα6>GAL4* to drive expression. This was examined using Real time RT-PCR
438 (Supplementary Figure 2). The Quantitative Real time RT-PCR examined the
439 levels of transcription from several drivers in crosses performed in the *dα6^{nx}*
440 background. A low level of background expression was confirmed for the
441 86Fb AttP landing site as expected from the rescue results (Supplementary
442 Tables 2 and 3) and published data regarding that landing site (Bischof et al.,
443 2013). This expression is clearly distinguishable from the rescue crosses
444 when using the *elav>GAL4*. There is not a significant difference in the
445 expression from the *Dα6>GAL4* compared to the parental *Dα6-3b8b*
446 background that is not being driven, however they are much more susceptible
447 to spinosad (41 corrected mortality vs -2 respectively at 0.05ppm, Figure 1D
448 vs Figure 2B – Graph 3b8b). Given the significant increase in spinosad
449 sensitivity observed with these drivers versus the insertion parental line, not
450 just the level but also the localisation of expression is most certainly causing
451 the difference in the phenotypes.

452 Expression occurring in cells that do not normally express *Dα6* might
453 not lead to the translation or correct assembly of receptors that are capable of
454 responding to spinosad. This is supported by the *FKBP59>GAL4* driver
455 results that do not rescue the spinosad resistance phenotype despite

456 neuronal expression being detected (Figure 1C and D). This could be due to
457 the lack of co-expression of other nAChR subunits that might, along with $D\alpha6$,
458 form a spinosad target or to the absence of other cellular proteins required for
459 the correct folding, chaperoning and trafficking of the protein or for synapse
460 formation between adjacent cells (Nakayama et al., 2014). Even if functional
461 $D\alpha6$ containing receptors are being formed and localised to a synapse in
462 these cells, they are obviously not involved in a process where inappropriate
463 signalling due to spinosad exposure leads to mortality. The expression
464 patterns we observe for the FKBP59>GAL4 line, together with rescue results
465 indicate that it is not likely to represent the expression of $D\alpha6$ or at least not
466 express the receptor subunit in regions where spinosad exerts its toxic effect
467 on $D\alpha6$ -containing receptors. Based on the rescue results from the
468 $D\alpha6$ >GAL4 driver crossed to UAS- $D\alpha6$ -3b8b, the expression pattern
469 observed with nGFP was at least a partial representation of the native $D\alpha6$
470 expression pattern that includes cells involved in the response to spinosad.
471

472 **3.4 Expression of $D\alpha1$, $D\alpha5$ and $D\alpha7$ nAChR subunits does not rescue** 473 **the spinosad response.**

474 We investigated the possibility that expression of other nAChR
475 subunits in cells that normally express $D\alpha6$ could give the same spinosad
476 phenotype. This was performed with the two most closely related subunits,
477 $D\alpha5$ (53/65% identity/similarity) and $D\alpha7$ (53/65% identity/similarity), as well
478 as $D\alpha1$ (12/26% identity/similarity) (Grauso et al., 2002). Expression was
479 driven with $D\alpha6$ >GAL4 to allow rescue in a limited number of cells shown to
480 produce a spinosad response when $D\alpha6$ was expressed (Section 3.3.4).

481 While these subunit proteins are also being expressed from their native loci,
482 we are effectively adding or enhancing expression levels in some D α 6
483 expressing cells.

484 Expression of D α 5, D α 7 or D α 1 subunits does not lead to any rescue
485 of susceptibility to spinosad at either the 0.05ppm or 1ppm dose (Figure 3).
486 This result provides evidence that the subunits examined, D α 1, D α 5 or D α 7
487 cannot replace the D α 6-mediated response to spinosad.

488 The lack of rescue by D α 7 concurs with the observation that oocyte
489 expression of D α 6 in combination with D α 7 has a negligible or substantially
490 inferior response to spinosad (Watson et al., 2010). Our D α 5 data suggest
491 D α 6 is required to mediate the toxic effect of spinosad. This is despite D α 6
492 being unable to respond to spinosad or ACh without D α 5 co-expression in
493 oocytes (Lansdell et al., 2012; Watson et al., 2010). D α 1 was not expected to
494 rescue and was selected as a more distantly related nAChR subunit to D α 6. It
495 is involved in a response to neonicotinoids and the alleles tested do not confer
496 spinosad resistance (Perry et al., 2012).

497 The similarity of the D α 5/D α 6/D α 7 subunits, particularly around the
498 protein region where the *Fo α 6* resistance associated mutation was reported
499 (Puinean et al., 2013), suggests that, while spinosad might bind in this region,
500 other domains in the D α 6 subunit could co-operatively bind spinosad.
501 Structural and spatial constraints in D α 5 and D α 7 subunits may also prevent
502 spinosad binding.

503

504 **3.5 Expression of D α 6 orthologues can rescue the spinosad response.**

505 $\alpha 6$ -mediated spinosad resistance has been reported in a number of
506 pest insects. We therefore tested $D\alpha 6$ orthologues from three taxonomically
507 diverse species, *M. domestica* (Diptera), *P. xylostella* (Lepidoptera) and *B.*
508 *ovis* (Phthiraptera) in the *D. melanogaster* expression system. Resistance has
509 been identified in *M. domestica* but there is no evidence it is linked to the $\alpha 6$ -
510 orthologue (Gao et al., 2007). Resistance has not been reported for *B. ovis*,
511 while *Px $\alpha 6$* has been directly associated with spinosad resistance (Baxter et
512 al., 2010). A protein sequence alignment illustrates the strong similarity of
513 these subunits (Figure 4). They have high homology but there are several
514 divergent regions, particularly beyond the TM3 domain, generally found to be
515 the least conserved region among nAChR subunits.

516 In order to have the best chance of detecting a spinosad response we
517 wanted to maximise the expression of these subunits in our system. Therefore
518 we used *elav>GAL4* as it provided a higher spinosad response and more
519 mRNA (Figures 2B vs 1D, and Supplementary Figure 2). Expression in the
520 *d $\alpha 6^{nx}$* background with *elav>GAL4*, results in phenotypic rescue with each of
521 the three *D $\alpha 6$* orthologues (Figure 5 A-C). The *P. xylostella* orthologue
522 confers sensitivity at 0.1ppm. Indeed the *UAS-Px $\alpha 6$ -3a8b* parental shows an
523 even higher spinosad response than that observed with any *Drosophila*
524 isoform parental line in the *d $\alpha 6^{nx}$* background (Figure 2B vs 5B). This is more
525 noticeable at higher doses (Supplementary Table 2 vs Figure 5B 0.3ppm
526 dose).

527 The *UAS-Md $\alpha 6$ -3b8a* *M. domestica* isoform was tested in the *d $\alpha 6^{nx}$*
528 background and the spinosad susceptible phenotype is rescued at 0.3ppm
529 (Figure 5A). In the *d $\alpha 6^{W337*}$* background there is a response at 0.1ppm,

530 highlighting the more susceptible nature of this allele (Supplementary Table
531 5). This could possibly be due to interactions of the proteins with the truncated
532 D α 6 protein.

533 The UAS-Px α 6-3b8a cross to elav>GAL4 provides a higher level of
534 response to spinosad than any of the *Drosophila* isoforms (Figure 5B). This is
535 particularly noticeable in the insertion parental line where there is a marked
536 increase in the susceptibility to spinosad compared to even the most
537 susceptible *D. melanogaster* isoform, UAS-D α 6-3a8a (Figure 2B). This could
538 mean that UAS-Px α 6-3b8a forms receptors that are more spinosad
539 responsive. There are several differences between it and the *Drosophila*
540 protein in the C-terminal region, the likely site of interaction with spinosad
541 (Figure 4) (Puinean et al., 2013).

542 *B. ovis* had two isoforms cloned and expressed, UAS-Bov α 6-3a8b and
543 UAS-Bov α 6-3a8a. The expression using elav>GAL4 shows both rescue the
544 response to spinosad, albeit at slightly different levels (Figure 5C). The rescue
545 is also lower than that of the respective *D. melanogaster* native isoforms. A
546 clone of the 3a8a isoform has not been reported for *D. melanogaster*
547 (Flybase: <http://flybase.org/reports/FBgn0032151.html>, accessed 2-Oct-2014),
548 however we were able to artificially construct one (Section 2.5.1). It was quite
549 responsive to spinosad when overexpressed (Figure 2B). This pattern holds
550 for the two *B. ovis* isoforms with UAS-Bov α 6-3a8b less responsive to
551 spinosad than UAS-Bov α 6-3a8a. A possibility is that in wildtype *D.*
552 *melanogaster* the suppression of this 3a8a isoform is due to its
553 pharmacological properties. Only the UAS-Bov α 6-3a8b isoform was tested in

554 the $d\alpha6^{W337*}$ allele background and the results from this were similar
555 (Supplementary Table 5).

556 The two *B. ovis* isoforms only differ at 8a vs 8b and in one other
557 residue in the N-terminal ligand binding region. This, along with variations in
558 the levels of rescue observed for different *D. melanogaster* splice isoforms,
559 highlights that spinosad sensitivity is significantly impacted by the variety and
560 proportions of splice isoforms that are produced. Isoform diversity and
561 abundance will vary in different cell types in one insect species and between
562 species.

563 The difference in the levels of rescue we observe between genes from
564 different species could be due to numerous, but not necessarily independent,
565 factors. The pest genes were not codon optimised for expression in *D.*
566 *melanogaster*. Therefore the differences in nucleotide coding could affect
567 translation due to codon bias or the differences in amino acid sequence
568 between the $\alpha6$ -orthologues. These differences could either decrease the
569 amount of receptor translated, reduce the capacity of spinosad to bind to the
570 receptor, make the receptor less responsive even if spinosad does bind or
571 alter the binding sites of accessory proteins that are required for wildtype $\alpha6$
572 containing receptors to be formed. Loss of binding interactions with
573 modulatory proteins or chaperones could lead to poorer function or impaired
574 assembly of a correct channel with other *Drosophila* nAChR subunits (Jones
575 et al., 2010).

576 Differences in the Bov $\alpha6$ and the Px $\alpha6$ protein sequence compared with
577 other dipteran orthologues are concentrated in the C-terminal region and in
578 the TM3-TM4 cytoplasmic loop. Thus there could be important differences

579 that lead to an altered capacity for spinosad binding or in the responsiveness
580 of the channel once spinosad binds and exerts its effect. While sequence
581 differences in this region of the $\alpha 6$ protein seem important for the spinosad
582 response, it is not possible pinpoint in the residues involved given the number
583 of residues that differ. The expression of chimeric (Somers et al., 2015) and/or
584 *in vitro* mutagenised $\alpha 6$ protein would be required to increase the resolution of
585 this analysis.

586 Besides the isoform variation between the tested constructs, there is a
587 103 amino acid stretch of almost perfect conservation between all species,
588 other than a T276S change in *B. ovis*, in transmembrane domains 1 to 3
589 (Figure 4). This level of conservation around the region predicted to have a
590 role in spinosad binding (Puinean et al., 2013) could explain the capacity of
591 spinosad to exert an effect on all of the insect $\alpha 6$ -like isoforms tested. It also
592 suggests a potential for $\alpha 6$ -mediated resistance to spinosad to evolve in many
593 insect species.

594 In recessive *d* $\alpha 6$ mutant alleles, expression of individual isoforms of
595 $D\alpha 6$ is sufficient to contribute to a spinosad binding site. Thus mutations that
596 only remove individual isoforms are not likely to confer high levels of
597 resistance, except in the case of a dominant negative allele (as observed in
598 Somers et al., 2015). This is supported by the types of mutations that have
599 thus far been identified as a cause of or associated with spinosad resistance
600 (Baxter et al., 2010; Puinean et al., 2013; Watson et al., 2010).

601 Spinosad resistance conferred by an $\alpha 6$ mutation has already arisen in
602 *P. xylostella* (Baxter et al., 2010). If the *Px* $\alpha 6$ expression studies performed
603 here had been conducted before field resistance arose, then the genetic basis

604 of resistance would have been correctly predicted. Based on our expression
605 studies with the *M. domestica* and *B. ovis* $\alpha 6$ -orthologues, there is a potential
606 for $\alpha 6$ -mediated resistance to evolve in these species. The spinosad binding
607 and response observed in our test system is likely to occur in the pests
608 themselves. Spinosad resistance has not yet evolved in *B. ovis* which could
609 be due to the way in which the insecticide is used, with direct individual
610 application to the host (sheep), or the fact that there are a number of effective
611 alternative insecticides for treatment of *B. ovis* available. In *M. domestica*
612 resistance has evolved, but not via an $\alpha 6$ -mediated mechanism as yet (Gao
613 et al., 2007). This could simply be because other resistance mechanisms
614 have evolved first. $\alpha 6$ -mediated target site resistance could arise later or not
615 at all, depending on patterns of spinosad usage. Under these circumstances
616 molecular screening of pest populations for $\alpha 6$ loss of function mutations may
617 be worthwhile. Loss or modification of $\alpha 6$ function may have greater fitness
618 costs in some species, with other mechanisms providing a better balance of
619 resistance and fitness to counter the prevailing levels of insecticide exposure.
620 Given that loss of $\alpha 6$ function confers resistance, mutations in genes involved
621 in the assembly and membrane localization of $\alpha 6$, or in maintaining synapses
622 (Nakayama et al., 2014) could confer resistance.

623

624 **4. Summary and conclusions**

625 This study demonstrates the capacity of individual insect $\alpha 6$ subunits to
626 rescue a response to spinosad with a high degree of sensitivity. The
627 development of a simple rescue paradigm allowed us to test and make some
628 comparisons between different species, and even within species (*D.*

629 *melanogaster and B. ovis.*) for different isoforms. The system also offers the
630 opportunity to investigate other aspects of $\alpha 6$ receptor biology through this
631 response to spinosad phenotype; artificial constructs may shed further light on
632 critical spinosad binding regions given that robust heterologous expression
633 systems are still being developed. There are many reasons why sensitivities
634 differ between all the isoforms and species tested, but in this study all
635 analysed rescue constructs had an easily detected response to spinosad,
636 supporting the notion that $\alpha 6$ containing nAChRs are a conserved target of
637 spinosad in a wide range of insect species.

638

639 **Acknowledgements** [L]
[SEP]

640 The authors would like to thank the providers of materials that were used in
641 this study; J. Bishof and K. Basler for providing their pUASattB vector,
642 Bloomington Stock centre for fly lines, the Australian Drosophila Biomedical
643 Research Support Facility for handling quarantine and importing flies, Novartis
644 Animal Health for *M. domestica* WHO/I sample, Queensland Department of
645 Primary Industries for *B.ovis* samples and S.W. Baxter for the *P. xylostella*
646 clone. They would also like to acknowledge sources of funding for the project,
647 Australian Research Council Discovery Grant (DP120100788 - PB) and an
648 Australian Wool Innovation Research Fellowship (TP) and J.N. Peters
649 Bequest Fellowship (TP).

650

651 **References**

652

653 Agosto, J., Choi, J.C., Parisky, K.M., Stilwell, G., Rosbash, M., Griffith, L.C.,
654 2008. Modulation of GABAA receptor desensitization uncouples sleep onset
655 and maintenance in Drosophila. Nat Neurosci 11, 354-359.

656 Bao, W.X., Narai, Y., Nakano, A., Kaneda, T., Murai, T., Sonoda, S., 2014.
657 Spinosad resistance of melon thrips, *Thrips palmi*, is conferred by G275E
658 mutation in alpha6 subunit of nicotinic acetylcholine receptor and cytochrome
659 P450 detoxification. Pesticide biochemistry and physiology 112, 51-55.

660 Baxter, S.W., Chen, M., Dawson, A., Zhao, J.Z., Vogel, H., Shelton, A.M.,
661 Heckel, D.G., Jiggins, C.D., 2010. Mis-spliced transcripts of nicotinic
662 acetylcholine receptor alpha6 are associated with field evolved spinosad
663 resistance in *Plutella xylostella* (L.). PLoS Genet 6, e1000802.

664 Bischof, J., Bjorklund, M., Furger, E., Schertel, C., Taipale, J., Basler, K.,
665 2013. A versatile platform for creating a comprehensive UAS-ORFeome
666 library in *Drosophila*. *Development* 140, 2434-2442.

667 Bischof, J., Maeda, R.K., Hediger, M., Karch, F., Basler, K., 2007. An
668 optimized transgenesis system for *Drosophila* using germ-line-specific phiC31
669 integrases. *Proc Natl Acad Sci U S A* 104, 3312-3317.

670 Edgar, R.C., 2004. MUSCLE: multiple sequence alignment with high accuracy
671 and high throughput. *Nucleic Acids Res* 32, 1792-1797.

672 Ffrench-Constant, R.H., 1994. The molecular and population genetics of
673 cyclodiene insecticide resistance. *Insect Biochem Mol Biol* 24, 335-345.

674 Gao, J.R., Deacutis, J.M., Scott, J.G., 2007. The nicotinic acetylcholine
675 receptor subunit M α 6 from *Musca domestica* is diversified via post-
676 transcriptional modification. *Insect Mol Biol* 16, 325-334.

677 Gouy, M., Guindon, S., Gascuel, O., 2010. SeaView version 4: A multiplatform
678 graphical user interface for sequence alignment and phylogenetic tree
679 building. *Mol Biol Evol* 27, 221-224.

680 Grauso, M., Reenan, R.A., Culetto, E., Sattelle, D.B., 2002. Novel putative
681 nicotinic acetylcholine receptor subunit genes, D α 5, D α 6 and D
682 α 7 in *Drosophila melanogaster* identify a new and highly conserved
683 target of adenosine deaminase acting on RNA-mediated A-to-I pre-mRNA
684 editing. *Genetics* 160, 1519-1533.

685 Herron, G.A., Gunning, R.V., Cottage, E.L., Borzatta, V., Gobbi, C., 2014.
686 Spinosad resistance, esterase isoenzymes and temporal synergism in
687 *Frankliniella occidentalis* (Pergande) in Australia. *Pesticide biochemistry and*
688 *physiology* 114, 32-37.

689 Hojland, D.H., Jensen, K.M., Kristensen, M., 2014. Expression of Xenobiotic
690 Metabolizing Cytochrome P450 Genes in a Spinosad-Resistant *Musca*
691 *domestica* L. Strain. PLoS One 9, e103689.

692 Hou, W., Liu, Q., Tian, L., Wu, Q., Zhang, Y., Xie, W., Wang, S., Miguel, K.S.,
693 Funderburk, J., Scott, J.G., 2014. The alpha6 nicotinic acetylcholine receptor
694 subunit of *Frankliniella occidentalis* is not involved in resistance to spinosad.
695 Pesticide biochemistry and physiology 111, 60-67.

696 Hsu, J.C., Feng, H.T., Wu, W.J., Geib, S.M., Mao, C.H., Vontas, J., 2012.
697 Truncated transcripts of nicotinic acetylcholine subunit gene Bdelta6 are
698 associated with spinosad resistance in *Bactrocera dorsalis*. Insect Biochem
699 Mol Biol 42, 806-815.

700 Jones, A.K., Buckingham, S.D., Sattelle, D.B., 2010. Proteins interacting with
701 nicotinic acetylcholine receptors: expanding functional and therapeutic
702 horizons. Trends Pharmacol Sci 31, 455-462.

703 Kirst, H.A., 2010. The spinosyn family of insecticides: realizing the potential of
704 natural products research. J Antibiot (Tokyo) 63, 101-111.

705 Lansdell, S.J., Collins, T., Goodchild, J., Millar, N.S., 2012. The *Drosophila*
706 nicotinic acetylcholine receptor subunits Dalpha5 and Dalpha7 form functional
707 homomeric and heteromeric ion channels. BMC neuroscience 13, 73.

708 Lansdell, S.J., Millar, N.S., 2004. Molecular characterization of Dalpha6 and
709 Dalpha7 nicotinic acetylcholine receptor subunits from *Drosophila*: formation
710 of a high-affinity alpha-bungarotoxin binding site revealed by expression of
711 subunit chimeras. J Neurochem 90, 479-489.

712 Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data
713 using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
714 Methods 25, 402-408.

715 McKenzie, J.A., Batterham, P., 1998. Predicting insecticide resistance:
716 mutagenesis, selection and response. Philos Trans R Soc Lond B Biol Sci
717 353, 1729-1734.

718 Nakayama, M., Matsushita, F., Hama, C., 2014. The Matrix Protein Hikaru
719 genki Localizes to Cholinergic Synaptic Clefts and Regulates Postsynaptic
720 Organization in the Drosophila Brain. J Neurosci 34, 13872-13877.

721 Perry, T., Batterham, P., Daborn, P.J., 2011. The biology of insecticidal
722 activity and resistance. Insect Biochem Mol Biol 41, 411-422.

723 Perry, T., Chan, J.Q., Batterham, P., Watson, G.B., Geng, C., Sparks, T.C.,
724 2012. Effects of mutations in Drosophila nicotinic acetylcholine receptor
725 subunits on sensitivity to insecticides targeting nicotinic acetylcholine
726 receptors. Pesticide biochemistry and physiology 102, 56-60.

727 Perry, T., Heckel, D.G., McKenzie, J.A., Batterham, P., 2008. Mutations in
728 Dalpha1 or Dbeta2 nicotinic acetylcholine receptor subunits can confer
729 resistance to neonicotinoids in Drosophila melanogaster. Insect Biochem Mol
730 Biol 38, 520-528.

731 Perry, T., McKenzie, J.A., Batterham, P., 2007. A Dalpha6 knockout strain of
732 Drosophila melanogaster confers a high level of resistance to spinosad. Insect
733 Biochem Mol Biol 37, 184-188.

734 Puinean, A.M., Lansdell, S.J., Collins, T., Bielza, P., Millar, N.S., 2013. A
735 nicotinic acetylcholine receptor transmembrane point mutation (G275E)

736 associated with resistance to spinosad in *Frankliniella occidentalis*. *J*
737 *Neurochem* 124, 590-601.

738 Rosenheim, J.A., Hoy, M.A., 1989. Confidence Intervals for the Abbott's
739 Formula Correction of Bioassay Data for Control Response. *Journal of*
740 *Economic Entomology* 82, 331-335.

741 Schulz, R., Bertrand, S., Chamaon, K., Smalla, K.H., Gundelfinger, E.D.,
742 Bertrand, D., 2000. Neuronal nicotinic acetylcholine receptors from
743 *Drosophila*: two different types of alpha subunits coassemble within the same
744 receptor complex. *J Neurochem* 74, 2537-2546.

745 Sharma, Y., Cheung, U., Larsen, E.W., Eberl, D.F., 2002. PPTGAL, a
746 convenient Gal4 P-element vector for testing expression of enhancer
747 fragments in *drosophila*. *Genesis* 34, 115-118.

748 Smyth, K.A., Parker, A.G., Yen, J.L., McKenzie, J.A., 1992. Selection of
749 dieldrin-resistant strains of *Lucilia cuprina* (Diptera: Calliphoridae) after ethyl
750 methanesulfonate mutagenesis of a susceptible strain. *J Econ Entomol* 85,
751 352-358.


752 Somers, J., Nguyen, J., Lumb, C., Batterham, P., Perry, T., 2015. In vivo
753 functional analysis of the *Drosophila melanogaster* nicotinic acetylcholine receptor
754 *Dα6* using the insecticide Spinosad. *Insect Biochem Mol Biol*

755 Watson, G.B., Chouinard, S.W., Cook, K.R., Geng, C., Gifford, J.M.,
756 Gustafson, G.D., Hasler, J.M., Larrinua, I.M., Letherer, T.J., Mitchell, J.C.,
757 Pak, W.L., Salgado, V.L., Sparks, T.C., Stilwell, G.E., 2010. A spinosyn-
758 sensitive *Drosophila melanogaster* nicotinic acetylcholine receptor identified
759 through chemically induced target site resistance, resistance gene

760 identification, and heterologous expression. *Insect Biochem Mol Biol* 40, 376-
761 384.

762 Zhang, H.G., Lee, H.J., Rocheleau, T., ffrench-Constant, R.H., Jackson, M.B.,
763 1995. Subunit composition determines picrotoxin and bicuculline sensitivity of
764 *Drosophila* gamma-aminobutyric acid receptors. *Mol Pharmacol* 48, 835-840.
765
766

767 **Figures**
768




769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787

Figure 1. Analysis of the Dα6 upstream genomic region for regulatory sequences.

A. Schematic of the genome region used for creating the enhancer>GAL4 constructs. The 1.692kb region is shown as a striped box. The beginning of the surrounding genes is indicated with a solid blue arrow. Lines under the region illustrate parts of the regions that are in each GAL4 construct. The names of the driver lines created are colored according to results in **D**. **B.** Light image (10X) of dissected third instar larval brain viewed dorsally from **C**. **C.** Flattened stack composite image of RFP (1.1kb) and GFP (0.6kb) channels (20X) of dissected third instar larval brain viewed dorsally. Scale bars for **B** and **C** are 200μm. Images taken using an EVOS® FLoid® Auto (Life Technologies) Label abbreviations – bh; brain hemisphere, cb; central brain, vg; ventral ganglion. **D.** Graph of mortality results from rescue crosses with different drivers controlling expression of UAS-Dα6-3b8b in the *da6^{nx}* background. Bars represent the UAS-Dα6-3b8b crossed with *elav*>GAL4 in light grey, with *Dα6*>GAL4 in dark grey and with *FKBP59*>GAL4 in white. 95% CI are shown.

Figure 2




788
789
790
791
792
793
794
795
796
797
798
799

Figure 2. Rescue of the spinosad susceptible phenotype using individual isoforms of Dα6.

Mortality results are shown from rescue experiments using UAS-Dα6 isoforms in the *dα6^{nx}* and *dα6^{W337*}* backgrounds. **A and C.** Background panels show ΦX-86Fb, elav>GAL4 and elav>GAL4 x ΦX-86Fb values are not significantly different to mortality on undosed media in the *dα6^{nx}* (**A**) and *dα6^{W337*}* (**C**) backgrounds. **B and D.** The graphs are labeled with the isoform used (3a8a, 3b8b, 3a8b and 3b8a). The bars are the homozygous insertion line (light grey) and the insertion driven by elav>GAL4 (dark grey) in the *dα6^{nx}* (**B**) and *dα6^{W337*}* (**D**) backgrounds. 95% CI are shown.

Figure 3



800
801
802
803
804
805
806


Figure 3. $D\alpha6>GAL4$ expression of different *Drosophila* nAChR subunits. Mortality results are shown from $\Phi X-86Fb$ empty AttP background, UAS- $D\alpha6-3b8b$, UAS- $D\alpha1$, UAS- $D\alpha5$ and UAS- $D\alpha7$ *Drosophila* nAChR subunits when expressed in the $d\alpha6^{nx}$ background using $D\alpha6>GAL4$. Only the UAS- $D\alpha6-3b8b$ construct was able to rescue the susceptibility to spinosad. 95% CI are shown.

Figure 4



807
 808 **Figure 4. Protein alignment of insect $\alpha 6$ subunits from this study.**
 809 MUSCLE protein alignment of insect $\alpha 6$ -like isoforms used in this study created
 810 with seaview (Gouy et al., 2010, Edgar, 2004). Predicted transmembrane
 811 domains are highlighted in green. Alternative exon 3a and 3b are in the dotted
 812 red box and alternative exon 8a and 8b in dotted blue box. Red numbering
 813 indicates RNA editing locations as per Grauso et al., 2002. The G301E mutation
 814 from *F. occidentalis*, Fo $\alpha 6$ is boxed in red. ▲ - site of the W337* mutation of
 815 *d $\alpha 6$ ^{W337*}* in this study and also the site of mis-splicing in a spinosad resistant
 816 strain of *P. xylostella* ((Baxter et al., 2010).
 817

Figure 5



818
819
820
821
822
823
824
825
826
827
828
829
830


Figure 5. Pest insect $\alpha 6$ subunits can rescue of susceptibility on spinosad when expressed using *elav*>GAL4.

Mortality results when using *elav*>GAL4 to drive expression of UAS constructs (Table 3) in the *da6^{nx}* background. The light shading represents the parental insertion line and dark shading represents the construct crossed to *elav*>GAL4. **A.** *M. domestica* rescue with the 3b8a isoform (Note the parental insertion was not tested on 0.1ppm. There was no significant difference observed in the driven construct at 0.1ppm spinosad). **B.** *P. xylostella* rescue with the 3a8b isoform. **C.** *B. ovis* rescue with the 3a8a (light grey - parental and dark grey - driven) and 3a8b (white - parental and black - driven) isoforms. 95% CI are shown.

831
832
833

Supplementary Figures and Tables

Figure S1. Identification of the $\alpha 6^{W337*}$ mutation




834
835
836
837
838
839
840
841
842
843

Figure S1. Identification of the $\alpha 6^{W337*}$ mutation

Sequence reads of two clones of $\alpha 6^{W337*}$ with the G>A transition causing the nonsense mutation W337* (Sequencher 4.7 Genecodes). RNA was isolated (Trizol) and cDNA made (SuperscriptIII – Invitrogen) and PCR performed on this from which products were ligated into pGEM-T-Easy and transformed. Plasmids were isolated with a miniprep kit (Promega) and sequenced at Macrogen (Korea) with vector primers T7 and SP6 and an internal primer (30DEX7F - GATTCGATGGCACGTATCAC).

Figure S2. Analysis of relative expression levels of $D\alpha 6$ transcripts



844

845

846 **Figure S2 Analysis of relative expression levels of $D\alpha 6$ transcripts**

847 Relative expression levels of $D\alpha 6$ transcripts in the $d\alpha 6^{nx}$ background for the

848 parental line UAS-Dα6-3b8b, (set equal to 1), and the parental line crossed to


849 different drivers. Clearly the elav>GAL4 driver expresses the transcript at the

850 highest level while in the $d\alpha 6^{nx}$ background control cross, elav>GAL4 x ΦX-86Fb,

851 $D\alpha 6$ transcript is barely detectable.

852

Figure S3. Analysis of *Dα6* enhancer constructs in pStinger vector.



854

855

Figure S3 Analysis of *Dα6* enhancer constructs in pStinger vector.

Nuclear green fluorescent protein (nGFP) expressed under control of both the FKBP59_0.6kb enhancer fragment (A-B) and the *Dα6*_1.1kb enhancer fragment (C-D), demonstrating the different expression patterns from these two DNA fragments. The two different images for each fragment represent the general expression pattern observed in the 3rd instar larval central nervous system and are from individual insertion events to control for possible position effects. All dorsal view. The FKBP59_0.6kb fragment (A-B) shows wide expression throughout the central nervous system, the *Dα6*_1.1kb (C-D) shows a more restricted expression pattern concentrated in the central brain and ventral ganglion. Images were taken on an Olympus SZX12 stereomicroscope attached to a mercury burner at 400x magnification through a GFP filter. Abbreviations –

868

869

870

Table S1. MIQE Table

Sample/Template	details	Checklist
Source	If cancer, was biopsy screened for adjacent normal tissue?	Drosophila melanogaster 1st instar
Method of preservation	Liquid N2/RNA later/formalin	Liquid N2
Storage time (if appropriate)	If using samples >6 months old	< 2 months old
Handling	fresh/frozen/formalin	Frozen
Extraction method	Trizol/columns	Trizol
RNA: DNA-free	Intron-spanning primers/no RT control	Intron-spanning primers, Dnaase, PCR check
Concentration	Nanodrop/vibrogen/microfluidics	Fluorometric Quantitation
RNA: integrity	Microfluidics/5'3' assay	Agarose Gel
Inhibition-free	Method of testing	Dilution curve, PCR efficiency less than 100%
Assay optimisation/validation		
Accession number	RefSeq XX_1214567	NM_001273373.2, NM_001201835.3, NM_205953.3, NM_205952.3, NM_135472.5, NM_205951.2, NM_164874.3
Amplicon details	exon location, amplicon size	243bp
Primer sequence	even if previously published	DanL1 CAATATCGCTCCCAAACC DanR1 TCGTGAAGAGCGTAAAACAA
Probe sequence*	identify LNA or other substitutions	N/A
In silico	BLAST/Primer-BLAST/in-silico	Primer-BLAST, electrophoresis, melt curve
empirical	primer concentration/annealing temperature	10uM, 61deg
Priming conditions	oligo-dT/random/combinator/target-specific	oligo-dT
PCR efficiency	dilution curve	Dan = 1.79 CG13220 = 1.86
Linear dynamic range	spanning unknown targets	2 fold serial dilution
Limits of detection	LOD detection/accurate quantification	Dan > CT 37, CG13220 > CT 35
Intra-assay variation	copy numbers not Cq	Dan = 0.19 CG13220 = 0.18
RT/PCR		
Protocols	detailed description, concentrations, volumes	12.5ul total reaction, 5ul Syngreen Master Mix, 0.25ul F, 0.25ul R, 4.5ul H2O and 2.5ul Template
Reagents	supplier, lot number	Quantifast SYBR green PCR kit, Qiagen
Duplicates RT	ACq	Triplicate
NTC	Cq & melt curves	CT value or melt curve not detected
NAC	ACq beginning/end of qPCR	N/A
Positive control	intra-run calibrator	Intra-run Calibrator
Data analysis		
Specialist software	e.g., QBasePlus	2-ΔΔCT method (Livak and Schmittgen, 2001)
Statistical justification	e.g., biological replicates	1 biological replication for each cross
Transparent, validated normalisation	e.g., GeNorm summary	Target and housekeeper validated at the same life stage

871
872
873

Table S2. elav>GAL4 x UAS-α6 corrected mortality (%) results in the *dα6^{nx}* background.

<i>dα6^{nx}</i>	0.05ppm	95%CI +/-	0.1ppm	95%CI +/-	0.3ppm	95%CI +/-
Background Controls						
ΦX-86Fb	-6%	10%	-4%	9%	3%	10%
elav>GAL4	-11%	15%	-10%	14%	-6%	16%
Insertion Parentals						
UAS-Dα6-3b8b	-6%	6%	10%	5%	66%	9%
UAS-Dα6-3a8a	4%	19%	7%	18%	95%	3%
UAS-Dα6-3b8a	3%	6%	8%	6%	28%	6%
UAS-Dα6-3a8b	0%	14%	1%	14%	82%	5%
Expression Crosses						
elav>GAL4 x ΦX-86Fb	0%	9%	0%	11%	2%	11%
elav>GAL4 x UAS-Dα6-3b8b	88%	7%	99%	2%	100%	0%
elav>GAL4 x UAS-Dα6-3a8a	95%	4%	100%	0%	100%	0%
elav>GAL4 x UAS-Dα6-3b8a	75%	7%	92%	3%	99%	1%
elav>GAL4 x UAS-Dα6-3a8b	83%	6%	99%	2%	100%	0%

Significant effect on mortality relative to undosed media.

874
875

Table S3. *elav>GAL4* x *UAS- $\alpha 6$* corrected mortality (%) results in the *d $\alpha 6^{W337*}$* background

<i>d$\alpha 6^{W337*}$</i>	0.05ppm	95%CI +/-	0.1ppm	95%CI +/-	0.3ppm	95%CI +/-
Background Controls						
Φ X-86Fb	8%	24%	8%	15%	5%	10%
<i>elav>GAL4</i>	2%	10%	0%	10%	17%	24%
Insertion Parentals						
<i>UAS-D$\alpha 6$-3b8b</i>	-1%	10%	4%	12%	66%	9%
<i>UAS-D$\alpha 6$-3a8a</i>	7%	11%	26%	5%	99%	1%
<i>UAS-D$\alpha 6$-3b8a</i>	5%	13%	15%	15%	37%	14%
<i>UAS-D$\alpha 6$-3a8b</i>	3%	15%	38%	11%	99%	2%
Expression Crosses						
<i>elav>GAL4</i> x Φ X-86Fb	-1%	33%	-2%	35%	0%	34%
<i>elav>GAL4</i> x <i>UAS-D$\alpha 6$-3b8b</i>	85%	6%	99%	1%	99%	1%
<i>elav>GAL4</i> x <i>UAS-D$\alpha 6$-3a8a</i>	77%	11%	98%	3%	99%	1%
<i>elav>GAL4</i> x <i>UAS-D$\alpha 6$-3b8a</i>	88%	4%	97%	2%	95%	4%
<i>elav>GAL4</i> x <i>UAS-D$\alpha 6$-3a8b</i>	82%	5%	99%	2%	100%	1%

Significant effect on mortality relative to undosed media.

876

877

Table S4. *D $\alpha 6$ >GAL4* x *UAS-D $\alpha 6$ -3b8b* corrected mortality (%) results in the *d $\alpha 6^{W337*}$* background

<i>d$\alpha 6^{W337*}$</i>	0.05ppm	95%CI +/-	0.1ppm	95%CI +/-	0.3ppm	95%CI +/-
Parental insertions						
<i>UAS-D$\alpha 6$-3b8b</i>	2%	25%	11%	28%	72%	8%
<i>D$\alpha 6$>GAL4</i>	5%	13%	2%	16%	-2%	13%
Expression Cross						
<i>D$\alpha 6$>GAL4</i> x <i>UAS-D$\alpha 6$-3b8b</i>	32%	15%	73%	7%	99%	1%

Significant effect on mortality relative to undosed media.

878

879

Table S5. Pest UAS- $\alpha 6$ expression corrected mortality (%) results in the $d\alpha 6^{W337*}$ background

$d\alpha 6^{W337*}$	0.05ppm	95%CI +/-	0.1ppm	95%CI +/-	0.3ppm	95%CI +/-	0.5ppm	95%CI +/-	1ppm	95%CI +/-	10ppm	95%CI +/-
Background Controls												
ΦX -86Fb	ND		-1%	17%	2%	13%	4%	18%	13%	13%	77%	11%
elav>GAL4	ND		-1%	14%	-8%	15%	3%	14%	5%	24%	34%	18%
Parental insertions												
UAS-D $\alpha 6$ -3b8b	ND		17%	15%	71%	15%	97%	2%	100%	0%	ND	
UAS-Md $\alpha 6$ -3b8a	ND		ND	8%			1%	7%	23%	9%	99%	1%
UAS-Bov $\alpha 6$ -3a8b	ND		ND		ND		2%	7%	7%	10%	ND	
UAS-Px $\alpha 6$ -3a8b	ND		40%	44%	99%	3%	100%	0%	100%	0%	100%	0%
Expression Crosses												
elav>GAL4 x UAS-D $\alpha 6$ -3b8b	73%	5%	94%	4%	100%	1%	100%	0%	100%	0%	100%	0%
elav>GAL4 x UAS-Md $\alpha 6$ -3b8a	ND		19%	17%	66%	9%	93%	4%	99%	1%	ND	
elav>GAL4 x UAS-Bov $\alpha 6$ -3a8b	ND		ND		66%	19%	81%	13%	97%	3%	ND	
elav>GAL4 x UAS-Px $\alpha 6$ -3a8b	88%	4%	99%	2%	100%	0%	100%	0%	100%	0%	100%	0%

Significant effect on mortality relative to undosed media.

ND – Not tested at that dose